Target intelligence / Profile preview

Lymphocyte depletion by ionizing radiation

01

Overview

Lymphocyte depletion by ionizing radiation refers to the decrease in lymphocyte (T cells, B cells, and NK cells) numbers following exposure to ionizing radiation, a recognized consequence of both therapeutic and accidental irradiation[7]. Lymphocytes are among the most radiosensitive cells in the body and can undergo rapid apoptosis due to DNA damage and oxidative stress caused by ionizing radiation[6][7]. The extent and persistence of depletion depend on the dose and duration of exposure; higher doses cause more pronounced and prolonged lymphopenia[3][5]. While this process can contribute to the immunosuppressive effects of radiation therapy (such as increased risk of infection), selective modulation of lymphocyte survival or function by radioprotective agents (e.g., taurine) is under investigation[6]. Lymphocyte depletion can also alter the balance and function of immune cell subtypes, with downstream effects on immune surveillance, inflammation, and potentially cancer development or progression[1][3][5]. Absolute lymphocyte count and lymphocyte functional assays may serve as biomarkers for monitoring these effects[1][4][5]. Summary: "Lymphocyte depletion by ionizing radiation" describes an *effect*, not a molecular target or receptor, and cannot be mapped to canonical drug target designations[3][5][6][7].

Other names
Lymphocyte reduction by ionizing radiationRadiation-induced lymphopeniaRadiation-related lymphocyte depletion
02

Mechanism of action

Radioprotectants: scavenging of free radicals, protection against apoptosis

03

Biological functions

Immune response (as affected by process)Cell death (specifically, apoptosis of immune cells)
04

Disease associations

Cancer (especially in the context of radiotherapy)ImmunosuppressionInflammatory disease (due to immune modulation)Other (increased risk of infection, impact on immune senescence)
05

Safety considerations

Risk of immune suppression and associated infectionsReduction in T and B cell populations, potentially long-lasting or permanentIncreased risk of secondary cancers or relapsed cancer
06

Interacting drugs

Antioxidants and radioprotective agents (e.g., taurine)

1 more in the full profile.

07

Biomarkers

Lymphocyte count (absolute lymphocyte number as a biomarker of immune status post-radiation)Telomere length in lymphocytes (as a marker of accelerated immune aging post-radiation)

Beyond the preview

Go deeper on Lymphocyte depletion by ionizing radiation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lymphocyte depletion by ionizing radiation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call